Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 in untreated gastric or GEJ adenocarcinoma
NCT07118527Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2025
- Primary completion
- Oct 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Suzhou Suncadia Biopharmaceutical. Started Aug 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07118527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118527.